塩田 真己

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Castration 59%
3. Androgen Receptors 45%
4. Androgens 35%
5. MDV 3100 16%
6. Docetaxel 16%
7. Urinary Bladder Neoplasms 15%
8. Y-Box-Binding Protein 1 14%
9. Survival 12%
10. Prostatectomy 12%
11. Therapeutics 11%
12. cabazitaxel 11%
13. Prostate-Specific Antigen 9%
14. Progression-Free Survival 9%
15. Neoplasms 9%
16. Growth 9%
17. Testosterone 8%
18. Drug Therapy 7%
19. Oxidative Stress 7%
20. Confidence Intervals 6%
21. Neoplasm Grading 6%
22. taxane 6%
23. abiraterone 5%
24. Recurrence 5%
25. Hormones 5%
26. Prostate 5%
27. Serum 5%